Deal Snapshot
Gilead Sciences to Acquire Immunomedics in a Transaction that Values Immunomedics at USD 21bn
Tuesday 15 September 2020

US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has agreed to acquire Immunomedics (NASDAQ: IMMU) for USD 88 per share in a cash transaction, the company said.

The transaction, which values Immunomedics at approximately USD 21bn, was unanimously approved by both the Gilead and Immunomedics Boards of directors and is anticipated to close during the fourth quarter of 2020.

Date Published: 15/09/2020